Epoetin alfa
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692034 |
| Pregnancy category |
|
| Routes of administration |
IV or subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C815H1317N233O241S5 |
| Molar mass | 18396.1 g/mol |
  (what is this?)
|
|
Epoetin alfa (rINN) /ɛˈpoʊ.ᵻtᵻn/ is a human erythropoietin produced in cell culture using recombinant DNA technology. Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
Epoetin is manufactured and marketed by Amgen under the trade name Epogen. Johnson & Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Products, LP), sells the same drug under the name Procrit, pursuant to a product license agreement. The average cost per patient in the U.S. was $8,447 in 2009. Darbepoetin alfa (rINN) /dɑːrbəˈpɔɪtᵻn/ is a glycosylation analog of erythropoietin containing two additional N-linked carbohydrate chains, also manufactured and marketed by Amgen, with a trade name of Aranesp. The FDA warnings and safety precautions for Procrit, Epogen and Aranesp are identical.
...
Wikipedia